FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Gullotta Tina
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/28/2020 

3. Issuer Name and Ticker or Trading Symbol

SUNESIS PHARMACEUTICALS INC [SNSS]
(Last)        (First)        (Middle)

SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
VP, Finance /
(Street)

SOUTH SAN FRANCISCO, CA 94080      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 14500 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)  (1)8/31/2028 Common Stock 40000 $2.18 D  
Stock Option (Right to Buy)  (2)12/31/2028 Common Stock 8611 $0.4157 D  
Stock Option (Right to Buy)  (3)3/29/2029 Common Stock 10000 $1.215 D  
Stock Option (Right to Buy)  (4)3/31/2030 Common Stock 70000 $0.4149 D  

Explanation of Responses:
(1) One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of August 31, 2018. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.
(2) One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of December 31, 2018. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.
(3) One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 29, 2019. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months.
(4) One fourth (1/4th) of the shares shall vest one (1) year from the Vesting Commencement Date of March 31, 2020. Thereafter, one forty-eighth (1/48th) of the shares granted shall vest monthly over the next thirty-six (36) months

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Gullotta Tina
SUNESIS PHARMACEUTICALS, INC.
395 OYSTER POINT BOULEVARD, SUITE 400
SOUTH SAN FRANCISCO, CA 94080


VP, Finance

Signatures
/s/ Tina Gullotta5/5/2020
**Signature of Reporting PersonDate

Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Sunesis Pharmaceuticals Charts.
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Sunesis Pharmaceuticals Charts.